Relapsed prostate cancer with neuroendocrine differentiation and high serum levels of carcinoembryonic antigen without elevation of prostrate-specific antigen: A case report

International Journal of Urology

Volumn 14, Issue 2, 2007, Pages 147-149

  Kinebuchi, Yoshiaki ^a   Noguchi, Wataru ^a   Irie, Kyoko ^a   Nakayama, Tsuyoshi ^a   Kato, Haruaki ^a   Nishizawa, Osamu ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Carcinoembryonic antigen (CEA); Neuroendocrine differentiation; Pro gastrin releasing peptide (ProGRP); Prostate cancer; Prostrate specific antigen (PSA)

Indexed keywords

BICALUTAMIDE; CARCINOEMBRYONIC ANTIGEN; CHROMOGRANIN A; ESTRAMUSTINE PHOSPHATE; ETOPOSIDE; FLUTAMIDE; LEUPRORELIN; PROGASTRIN RELEASING PEPTIDE; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; ARTICLE; BRAIN DISEASE; CANCER RELAPSE; CANCER STAGING; CASE REPORT; CELL DIFFERENTIATION; CONSTIPATION; DISEASE COURSE; DRUG SUBSTITUTION; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; IRRADIATION; MALE; MICTURITION; MORTALITY; MULTIPLE CYCLE TREATMENT; NEUROSECRETORY CELL; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATE CANCER; TRANSRECTAL ULTRASONOGRAPHY; TRANSURETHRAL NEEDLE ABLATION; URETHRAL BLEEDING;

ADENOCARCINOMA; CARCINOEMBRYONIC ANTIGEN; FATAL OUTCOME; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 33846307483     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2007.01616.x     Document Type: Article

References (10)

1. di Sant' Agnese PA, Cockett ATK. The prostatic endocrine-paracrine (neuroendocrine) regulatory system and neuroendocrine differentiation in prostatic carcinoma: a review and future directions in basic research. J. Urol. 1994; 152: 1927-31.
2. Sciarra A, Mariotti G, Gentile V et al. Neuroendocrine differentiation in human prostatic tissue: is it detectable and treatable? BJU Int. 2003; 91: 438-45.
3. Yashi M, Nukui A, Kurokawa S et al. Elevated serum progastrin-releasing polypeptide (31-98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer. Prostate 2003; 56: 305-12.
4. Feuer JA, Lush RM, Venzon D et al. Elevated carcinoembryonic antigen in patients with androgen independent prostate cancer. J. Investig. Med. 1998; 46: 66-72.
5. Sella A, Konichezky M, Flex D, Sulkes A, Baniel J. Low PSA metastatic androgen independent prostate cancer. Eur. Urol. 2000; 38: 250-4.
6. Yamamoto S, Ito T, Akiyama A, Aizawa T, Miki M, Tachibana M. M1 prostate cancer with a serum level of prostate specific antigen less than 10 ng/mL. Int. J. Urol. 2001; 8: 374-9.
7. Tanaka M, Suzuki Y, Taoka K et al. Progression of prostate cancer to neuroendocrine cell tumor. Int. J. Urol. 2001; 8: 431-6.
8. Ishizu K, Tsushimi M, Shimajiri S, Hamada T, Sasaguri Y, Naito K. Small cell carcimona of the prostate successfully treated with combined chemotherapy and radiotherapy: a case report. Hinyokika Kiyo 2002; 48: 97-100.
9. Sciarra A, Bosman C, Monti G et al. Somatostatin analogues and estrogens in the treatment of androgen ablation refractory prostate adenocarcinoma. J. Urol. 2004; 172: 1775-83.
10. Dimopoulos MA, Panopoulos C, Bamia C et al. Oral estramustine and oral etoposide for hormone- refractory prostate cancer. Urology 1997; 50: 754-8.